ChromaDex (CDXC) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

CDXC Stock Forecast


ChromaDex stock forecast is as follows: a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.

CDXC Analyst Ratings


Buy

According to 1 Wall Street analysts, ChromaDex's rating consensus is 'Buy'. The analyst rating breakdown for CDXC stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Jun 18, 2022H.C. WainwrightBuyBuyHold

ChromaDex's last stock rating was published by H.C. Wainwright on Jun 18, 2022. The company gave CDXC a "Buy" rating, the same as its previous rate.

ChromaDex Financial Forecast


ChromaDex Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue------------$29.45M$27.02M-$22.56M$21.00M$17.06M$16.73M$17.26M$17.76M$17.31M$17.70M$14.68M$15.45M$14.18M$15.29M$14.35M$13.09M$12.05M
Avg Forecast$36.40M$35.25M$32.40M$31.80M$31.52M$30.50M$28.52M$27.75M$26.77M$24.03M$23.32M$23.48M$20.81M$20.30M$19.42M$19.41M$21.14M$18.69M$18.68M$17.52M$18.57M$17.18M$17.16M$16.68M$15.36M$14.29M$14.32M$13.59M$12.97M$11.52M
High Forecast$37.80M$36.61M$33.65M$33.03M$32.74M$31.68M$29.62M$28.19M$27.66M$24.03M$24.22M$24.38M$21.31M$21.08M$20.17M$20.15M$21.95M$18.69M$18.68M$17.52M$18.57M$17.18M$17.16M$16.68M$15.36M$14.29M$14.32M$13.59M$12.97M$11.52M
Low Forecast$34.83M$33.73M$31.00M$30.43M$30.17M$29.18M$27.29M$27.31M$25.89M$24.03M$22.32M$22.46M$20.31M$19.42M$18.58M$18.57M$20.22M$18.69M$18.68M$17.52M$18.57M$17.18M$17.16M$16.68M$15.36M$14.29M$14.32M$13.59M$12.97M$11.52M
# Analysts111111133111211111111111999955
Surprise %------------1.42%1.33%-1.16%0.99%0.91%0.90%0.98%0.96%1.01%1.03%0.88%1.01%0.99%1.07%1.06%1.01%1.05%

ChromaDex's average Quarter revenue forecast for Mar 24 based on 1 analysts is $23.48M, with a low forecast of $22.46M, and a high forecast of $24.38M. CDXC's average Quarter revenue forecast represents a -20.30% decrease compared to the company's last Quarter revenue of $29.45M (Dec 23).

ChromaDex EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts111111133111211111111111999955
EBITDA------------$-168.00K$-1.15M-$-1.97M$-1.44M$-531.00K$-5.96M$-7.18M$-4.93M$-8.43M$-5.14M$-6.96M$-5.69M$-3.82M$-3.31M$-5.52M$-8.50M$-6.49M
Avg Forecast$-11.71M$-11.34M$-10.43M$-10.23M$-10.14M$-9.82M$-9.18M$-8.93M$-8.62M$-7.73M$-7.51M$-7.55M$-6.70M$-6.53M$-6.25M$-6.24M$-6.80M$-6.25M$-6.25M$-5.59M$-6.21M$-5.75M$-5.74M$-4.64M$-5.14M$-4.78M$-4.79M$-6.04M$-4.34M$-3.86M
High Forecast$-11.21M$-10.85M$-9.98M$-9.79M$-9.71M$-9.39M$-8.78M$-8.79M$-8.33M$-7.73M$-7.18M$-7.23M$-6.54M$-6.25M$-5.98M$-5.98M$-6.51M$-6.25M$-6.25M$-4.47M$-6.21M$-5.75M$-5.74M$-3.71M$-5.14M$-4.78M$-4.79M$-4.83M$-4.34M$-3.86M
Low Forecast$-12.17M$-11.78M$-10.83M$-10.63M$-10.54M$-10.19M$-9.53M$-9.07M$-8.90M$-7.73M$-7.80M$-7.85M$-6.86M$-6.78M$-6.49M$-6.49M$-7.06M$-6.25M$-6.25M$-6.70M$-6.21M$-5.75M$-5.74M$-5.56M$-5.14M$-4.78M$-4.79M$-7.24M$-4.34M$-3.86M
Surprise %------------0.03%0.18%-0.32%0.21%0.08%0.95%1.29%0.79%1.47%0.89%1.50%1.11%0.80%0.69%0.91%1.96%1.68%

undefined analysts predict CDXC's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than ChromaDex's previous annual EBITDA (undefined) of $NaN.

ChromaDex Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts111111133111211111111111999955
Net Income------------$114.00K$-959.00K-$-1.33M$673.00K$1.09M$-6.41M$-7.75M$-5.33M$-8.87M$-5.58M$-7.40M$-6.11M$-4.23M$-3.73M$-5.93M$-8.84M$-7.20M
Avg Forecast$4.28M$3.89M$2.72M$2.33M$3.50M$2.92M$2.33M$1.54M$1.75M$445.22K$-1.56M$-1.56M$-1.75M$-2.33M$-3.11M$-3.62M$-1.94M$-4.66M$-6.35M$-6.02M$-7.50M$-6.98M$-6.20M$-4.92M$-7.18M$-7.40M$-7.56M$-6.44M$-8.16M$-8.31M
High Forecast$4.49M$4.08M$2.86M$2.45M$3.67M$3.06M$2.45M$1.55M$1.84M$455.91K$-1.47M$-1.47M$-1.65M$-2.20M$-2.94M$-3.42M$-1.84M$-4.66M$-6.35M$-4.82M$-7.50M$-6.98M$-6.20M$-3.94M$-7.18M$-7.40M$-7.56M$-5.15M$-8.16M$-8.31M
Low Forecast$4.04M$3.67M$2.57M$2.20M$3.30M$2.75M$2.20M$1.53M$1.65M$434.53K$-1.63M$-1.63M$-1.84M$-2.45M$-3.27M$-3.80M$-2.04M$-4.66M$-6.35M$-7.22M$-7.50M$-6.98M$-6.20M$-5.90M$-7.18M$-7.40M$-7.56M$-7.73M$-8.16M$-8.31M
Surprise %-------------0.07%0.41%-0.37%-0.35%-0.24%1.01%1.29%0.71%1.27%0.90%1.50%0.85%0.57%0.49%0.92%1.08%0.87%

ChromaDex's average Quarter net income forecast for Mar 24 is $-1.56M, with a range of $-1.63M to $-1.47M. CDXC's average Quarter net income forecast represents a -1464.35% decrease compared to the company's last Quarter net income of $114.00K (Dec 23).

ChromaDex SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts111111133111211111111111999955
SG&A------------$11.95M$11.88M-$14.29M$12.18M$12.05M$15.18M$17.19M$15.14M$18.42M$15.36M$15.77M$14.51M$11.77M$11.83M$13.28M$15.19M$12.59M
Avg Forecast$31.76M$30.76M$28.27M$27.75M$27.51M$26.61M$24.89M$24.21M$23.36M$20.97M$20.35M$20.48M$18.16M$17.71M$16.94M$16.93M$18.44M$16.14M$16.13M$13.37M$16.04M$14.83M$14.82M$10.51M$13.27M$12.34M$12.37M$11.73M$11.20M$9.95M
High Forecast$32.98M$31.94M$29.36M$28.82M$28.57M$27.64M$25.85M$24.59M$24.14M$20.97M$21.14M$21.27M$18.60M$18.39M$17.60M$17.58M$19.15M$16.14M$16.13M$16.04M$16.04M$14.83M$14.82M$12.62M$13.27M$12.34M$12.37M$11.73M$11.20M$9.95M
Low Forecast$30.39M$29.43M$27.05M$26.55M$26.32M$25.46M$23.81M$23.83M$22.59M$20.97M$19.47M$19.60M$17.72M$16.94M$16.21M$16.20M$17.65M$16.14M$16.13M$10.69M$16.04M$14.83M$14.82M$8.41M$13.27M$12.34M$12.37M$11.73M$11.20M$9.95M
Surprise %------------0.66%0.67%-0.84%0.66%0.75%0.94%1.29%0.94%1.24%1.04%1.50%1.09%0.95%0.96%1.13%1.36%1.27%

ChromaDex's average Quarter SG&A projection for Mar 24 is $20.48M, based on 1 Wall Street analysts, with a range of $19.60M to $21.27M. The forecast indicates a 71.46% rise compared to CDXC last annual SG&A of $11.95M (Dec 23).

ChromaDex EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts111111133111211111111111999955
EPS-------------$-0.01-$-0.02$0.01$0.02$-0.09$-0.11$-0.08$-0.13$-0.08$-0.12$-0.10$-0.07$-0.06$-0.10$-0.15$-0.14
Avg Forecast$0.06$0.05$0.04$0.03$0.04$0.04$0.03$0.02$0.02$0.01$-0.02$-0.02$-0.02$-0.03$-0.04$-0.05$-0.03$-0.06$-0.08$-0.09$-0.10$-0.09$-0.08$-0.09$-0.10$-0.10$-0.10$-0.11$-0.11$-0.11
High Forecast$0.06$0.05$0.04$0.03$0.05$0.04$0.03$0.02$0.02$0.01$-0.02$-0.02$-0.02$-0.03$-0.04$-0.04$-0.02$-0.06$-0.08$-0.09$-0.10$-0.09$-0.08$-0.09$-0.10$-0.10$-0.10$-0.11$-0.11$-0.11
Low Forecast$0.05$0.05$0.03$0.03$0.04$0.04$0.03$0.02$0.02$0.01$-0.02$-0.02$-0.02$-0.03$-0.04$-0.05$-0.03$-0.06$-0.08$-0.09$-0.10$-0.09$-0.08$-0.09$-0.10$-0.10$-0.10$-0.11$-0.11$-0.11
Surprise %-------------0.07%0.43%-0.38%-0.36%-0.26%1.12%1.24%0.79%1.41%1.00%1.40%1.04%0.70%0.61%0.90%1.39%1.27%

According to 1 Wall Street analysts, ChromaDex's projected average Quarter EPS for Mar 24 is $-0.02, with a low estimate of $-0.02 and a high estimate of $-0.02. This represents a -1433.33% decrease compared to CDXC previous annual EPS of - (Dec 23).

ChromaDex Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
NKTXNkarta$2.27$21.60851.54%Buy
AVTEAerovate Therapeutics$2.56$13.00407.81%Hold
ANEBAnebulo Pharmaceuticals$1.31$6.00358.02%Buy
IPSCCentury Therapeutics$1.17$5.00327.35%Buy
ANTXAN2 Therapeutics$1.34$5.00273.13%Buy
ACRVAcrivon Therapeutics$7.21$22.50212.07%Buy
KZRKezar Life Sciences$6.52$17.50168.40%Buy
MLYSMineralys Therapeutics$12.35$30.00142.91%Buy
ADAGAdagene$2.10$5.00138.10%Buy
RZLTRezolute$4.44$6.6750.23%Buy
JANXJanux Therapeutics$59.61$70.2517.85%Buy
CDXCChromaDex$6.00$5.50-8.33%Buy
IKNAIkena Oncology$1.62$1.33-17.90%Buy
XCURExicure$18.53$12.00-35.24%

CDXC Forecast FAQ


Is ChromaDex a good buy?

Yes, according to 1 Wall Street analysts, ChromaDex (CDXC) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of CDXC's total ratings.

What are ChromaDex's analysts' financial forecasts?

ChromaDex's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $118.3M (high $122.23M, low $113.96M), average EBITDA is $-38.07M (high $-36.672M, low $-39.334M), average net income is $10.28M (high $10.73M, low $9.78M), average SG&A $103.22M (high $106.65M, low $99.43M), and average EPS is $0.132 (high $0.138, low $0.126). CDXC's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $135.85M (high $141.09M, low $129.99M), average EBITDA is $-43.718M (high $-41.832M, low $-45.403M), average net income is $13.22M (high $13.88M, low $12.48M), average SG&A $118.53M (high $123.1M, low $113.42M), and average EPS is $0.17 (high $0.179, low $0.16).

Did the CDXC's actual financial results beat the analysts' financial forecasts?

Based on ChromaDex's last annual report (Dec 2023), the company's revenue was $116.36M, beating the average analysts forecast of $79.93M by 45.57%. Apple's EBITDA was $-5.599M, missing the average prediction of $-25.723M by -78.23%. The company's net income was $-4.938M, missing the average estimation of $-10.816M by -54.35%. Apple's SG&A was $51.42M, missing the average forecast of $69.74M by -26.27%. Lastly, the company's EPS was $-0.0659, missing the average prediction of $-0.139 by -52.62%. In terms of the last quarterly report (Dec 2023), ChromaDex's revenue was $29.46M, beating the average analysts' forecast of $20.81M by 41.53%. The company's EBITDA was $-168K, missing the average prediction of $-6.698M by -97.49%. ChromaDex's net income was $114K, missing the average estimation of $-1.75M by -106.52%. The company's SG&A was $11.95M, missing the average forecast of $18.16M by -34.21%. Lastly, the company's EPS was $0.0015, missing the average prediction of $-0.0225 by -106.67%